Alpha-2 Antiplasmin: US, Europe, Japan Test Volume Forecasts by Country and Market Segment through 2018

News provided by

Nov 14, 2011, 06:23 EST

NEW YORK, Nov. 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Test-Volume-Forecasts-by-Country-and-Market-Segment-through-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title='Alpha-2 Antiplasmin: US, Europe, Japan

Test Volume Forecasts by Country and Market Segment through 2018'>Alpha-2 Antiplasmin: US, Europe, Japan

Test Volume Forecasts by Country and Market Segment through 2018

http://www.reportlinker.com/p0365444/Alpha-2-Antiplasmin-US-Europe-Japan

Test-Volume-Forecasts-by-Country-and-Market-Segment-through-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and Alpha-2 Antiplasmin testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the Alpha-2 Antiplasmin testing closer to the patient, creating additional opportunities and challenges for suppliers.

This report presents a detailed analysis of the Alpha-2 Antiplasmin testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5- and 10-year test volume forecasts by country and market segment.

The report examines market applications of chromogenic substrates, monoclonal antibodies, immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 195 pages and 8 tables

Table of Contents

I. Introduction

II. Worldwide Market and Technology Overview

A. Introduction

B. Alpha-2 Antiplasmin: Clinical Significance

and Current Laboratory Procedures

C. Instrumentation Review

Introduction

Benk Hemolab

Benk TRT Thrombotimer

Bio/Data MCA 310

Bio/Data MCA 210

Bio/Data PAP-4C D/4D/4C

Cardiovascular Diagnostics COAG

Diagnostica Stago STA Compact

Diagnostica Stago STA-R

Diagnostica Stago Star 4/8

Helena Laboratories Cascade 480

Helena Laboratories Cascade M

Helena Laboratories PACKS-4

Helena THOR

Instrumentation Laboratory ACL 100 and 1000 series

Instrumentation Laboratory ACL6000

Instrumentation Laboratory ACL7000

Instrumentation Laboratory ACL9000

Instrumentation Laboratory Electra 1000C

Instrumentation Laboratory Electra 1400C

Instrumentation Laboratory Electra 1600/C

Instrumentation Laboratory Electra 1800C

Instrumentation Laboratory Futura

ITC Hemochron 8000

Roche Diagnostics CoaguChek

Siemens BCS

Siemens BCT

Siemens BF II/Fibrintimer Series

Sysmex CA-50

Sysmex CA-500

Sysmex CA-1500

Sysmex CA-5000/CA-1000

Sysmex CA-6000

Sysmex CA-7000

Teco Coatron II/Jr./AccuStasis 5000

Trinity Biotech Amax CS190

Trinity Biotech Amax CS400

Trinity Biotech Coag-A-Mate Max

Trinity Biotech KC 40, 4A, 1A Series

Trinity Biotech MDA 180

Trinity Biotech Coag-A-Mate MTX

Trinity Biotech Coag-A-Mate RA4

Trinity Biotech Coag-A-Mate XC/Plus

Trinity Biotech Coag-A-Mate XM

D. Major in Vitro Diagnostic Technologies and Their

Potential Applications

1. Chromogenic Substrates

2. Monoclonal and Polyclonal Antibodies

3. Immunoassays

a. Applications

b. Technological Principle

c. Enzyme Immunoassays (EIA)

Overview

ELISA

EMIT

Dot Immunobinding Assays

Capillary Immunoassays

Enzyme Amplification

Electrochemical Immunoassay

d. Fluorescent Immunoassays

Fluorescence Polarization

Time-Resolved Pulse Fluorescence

Fluorescence Lifetime

e. Latex Agglutination

f. Immunoprecipitation

4. Microcomputers

5. Automation

6. Robotics

7. DNA Probes

a. Overview

b. Amplification Methods

PCR

Ligase Chain Reaction

Branched DNA

Q-Beta Replicase

NASBA

SDA

3 SR

HPA

Two-Tiered System

LAT

8. Artificial Intelligence

9. Dry Chemistry

10. Biosensors

III. France: Test Volume Forecasts by Market Segment

IV. Germany: Test Volume Forecasts by Market Segment

V. Italy: Test Volume Forecasts by Market Segment

VI. Japan: Test Volume Forecasts by Market Segment

VII. Spain: Test Volume Forecasts by Market Segment

VIII. UK: Test Volume Forecasts by Market Segment

IX. USA: Test Volume Forecasts by Market Segment

X. Design Criteria For Decentralized Testing Products

XI. Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies for Decentralized Testing Market

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types Of Distributors

7. Market Segmentation

XII. Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

XIII. Competitive Assessments

Abbott

American Diagnostica

Avocet Medical

Axis-Shield

Beckman Coulter

Becton Dickinson

Bio/Data Corporation

Biosite

Chrono-Log

Corgenix Medical

Diagnostica Stago

Helena Laboratories

HYPEN BioMed

Instrumentation Laboratory

ITC

Nanogen

Roche

Siemens

Sienco

Sysmex

Thermo Fischer

Trinity Biotech

ZyCare

List of Tables

Major Companies Developing or Marketing Alpha-2 Antiplasmin Tests

France